To make clear the clinical importance of eIF3c in the resistance to EGFR-TKI, we performed eIF3c immunohistochemistry analysis on 27 lung tumor biopsy samples from EGFR-sensitizing mutant NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.